Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting
toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion
(RDE)s of INCA036978 administered as monotherapy and in combination with a standard
disease-direc...
Age: 18 years - 66+
Gender: All
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety and tolerability of INCA035784 in
participants with myeloproliferative neoplasms.
Age: 18 years - 66+
Gender: All
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, dose-limiting
toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s)
for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With
Ruxolitin...
Age: 18 years - 66+
Gender: All
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
The primary objective of this study is to assess the safety and tolerability of
administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to
enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks.
Patients ...
Age: 18 years - 66+
Gender: All
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with
ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Age: 18 years - 66+
Gender: All
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS
(Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary
Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essenti...
Age: 18 years - 66+
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Research Tissue Bank
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: - Peripheral blood - Bone marrow - Bone marrow biopsy - A phlebotomized unit of blood - Spleen cells - Toenail clippings This material will be used fo...
Age: 18 years - 66+
Gender: All
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material deriv...
Age: 18 years - 66+
Gender: All